We are live on
!
Find out more
DekaBank Deutsche Girozentrale Portfolio holdings
AUM
$59.2B
1-Year Est. Return
26.02%
This Fund
S&P 500
This Quarter
Est. Return
+4.26%
1 Year Est. Return
+26.02%
3 Year Est. Return
+92.08%
5 Year Est. Return
+125.09%
10 Year Est. Return
+457.34%
AUM
$19.9B
AUM Growth
+$3.15B
(+19%)
Cap. Flow
+$2.87B
Cap. Flow
% of AUM
14.37%
Top 10 Holdings %
Top 10 Hldgs %
18.32%
Holding
1,356
New
166
Increased
640
Reduced
325
Closed
204
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$179M |
| 2 |
Amazon
AMZN
|
+$121M |
| 3 |
Alibaba
BABA
|
+$111M |
| 4 |
Merck
MRK
|
+$94.9M |
| 5 |
Comcast
CMCSA
|
+$78.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$88.1M |
| 2 |
Cisco
CSCO
|
+$82.5M |
| 3 |
NextEra Energy
NEE
|
+$74.9M |
| 4 |
Union Pacific
UNP
|
+$52M |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$46.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.7% |
| 2 | Healthcare | 17.64% |
| 3 | Financials | 13.64% |
| 4 | Communication Services | 10.78% |
| 5 | Industrials | 8.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACHN
976
DELISTED
Achillion Pharmaceuticals
ACHN
| $289K | ﹤0.01% |
108,600
+42,300
| +64% | +$125K |
|
977
Collegium Pharmaceutical
COLL
$956M
| $286K | ﹤0.01% |
21,600
+8,400
| +64% | +$112K |
|
978
Banco Santander Chile
BSAC
$16.6B
| $285K | ﹤0.01% |
9,576
| – | – |
|
|
AMAG
979
DELISTED
AMAG Pharmaceuticals
AMAG
| $283K | ﹤0.01% |
29,700
+11,550
| +64% | +$125K |
|
980
Puma Biotechnology
PBYI
$454M
| $282K | ﹤0.01% |
22,158
+11,658
| +111% | +$268K |
|
981
Royal Gold
RGLD
$19.5B
| $282K | ﹤0.01% |
2,762
-2,046
| -43% | -$184K |
|
|
WNS
982
DELISTED
WNS Holdings
WNS
| $278K | ﹤0.01% |
4,712
| – | – |
|
983
Sociedad Química y Minera de Chile
SQM
$20.6B
| $271K | ﹤0.01% |
8,600
-13,000
| -60% | -$443K |
|
|
BBBY
984
DELISTED
Bed Bath & Beyond Inc
BBBY
| $271K | ﹤0.01% |
23,638
+23,038
| +3,840% | +$342K |
|
|
ACOR
985
DELISTED
Acorda Therapeutics
ACOR
| $269K | ﹤0.01% |
303
+89
| +42% | +$109K |
|
986
ICL Group
ICL
$6.85B
| $264K | ﹤0.01% |
50,387
+31,386
| +165% | +$166K |
|
|
VSLR
987
DELISTED
VIVINT SOLAR, INC.
VSLR
| $263K | ﹤0.01% |
36,057
+7,981
| +28% | +$50.4K |
|
988
MGIC Investment
MTG
$6.25B
| $262K | ﹤0.01% |
19,923
+15,123
| +315% | +$210K |
|
989
CytomX Therapeutics
CTMX
$754M
| $257K | ﹤0.01% |
24,200
+9,500
| +65% | +$99.6K |
|
990
Prothena Corp
PRTA
$450M
| $255K | ﹤0.01% |
25,300
+9,850
| +64% | +$101K |
|
991
Grupo Aeroportuario del Sureste
ASR
$8.3B
| $254K | ﹤0.01% |
1,496
| – | – |
|
992
Grupo Aeroportuario del Pacifico
PAC
$13.3B
| $253K | ﹤0.01% |
2,368
| – | – |
|
|
STOR
993
DELISTED
STORE Capital Corporation
STOR
| $253K | ﹤0.01% |
7,627
+1,764
| +30% | +$59.5K |
|
|
CBIO
994
Crescent Biopharma
CBIO
$626M
| $251K | ﹤0.01% |
218
+84
| +63% | +$100K |
|
995
Rigel Pharmaceuticals
RIGL
$750M
| $250K | ﹤0.01% |
10,200
+3,950
| +63% | +$89.2K |
|
|
PGNX
996
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $250K | ﹤0.01% |
43,000
+16,500
| +62% | +$79.6K |
|
997
Vanda Pharmaceuticals
VNDA
$302M
| $248K | ﹤0.01% |
17,200
+6,600
| +62% | +$105K |
|
|
HSII
998
DELISTED
Heidrick & Struggles
HSII
| $241K | ﹤0.01% |
+8,166
| New | +$286K |
|
999
British American Tobacco
BTI
$128B
| $237K | ﹤0.01% |
6,785
+106
| +2% | +$4.02K |
|
1000
Itaú Unibanco
ITUB
$87.5B
| $236K | ﹤0.01% |
34,559
-2,224
| -6% | -$14K |
|
Similar funds
QCM
NAMI
DekaBank Deutsche Girozentrale's Q2 2019 Portfolio in Review
As of Q2 2019, DekaBank Deutsche Girozentrale held 1,356 positions worth $19.9B, up 19% from $16.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
DekaBank Deutsche Girozentrale deployed $2.87B of net new capital in Q2 2019, opening 166 new positions and adding to 640 existing holdings. Its largest new stake was Alcon: 743,373 shares worth $45.4M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was TSMC, an estimated $88.1M trimmed.
- DekaBank Deutsche Girozentrale's largest Q2 2019 buy was Alcon: 743,373 shares worth $45.4M.
- DekaBank Deutsche Girozentrale added most to Procter & Gamble in Q2 2019, an estimated $179M increase.
- DekaBank Deutsche Girozentrale's biggest Q2 2019 reduction was TSMC, cutting an estimated $88.1M.
- DekaBank Deutsche Girozentrale fully exited Express Scripts Holding Company in Q2 2019, selling an estimated $46.5M.
- DekaBank Deutsche Girozentrale's ten largest holdings make up 18% of its $19.9B portfolio in Q2 2019.
- DekaBank Deutsche Girozentrale opened 166 new positions and closed 204 in Q2 2019.
- DekaBank Deutsche Girozentrale's portfolio value rose 19% quarter-over-quarter to $19.9B.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2019, filed 1 Aug 2019.